BOFAS Abstracts Archive

You can search for abstracts by using the search bar below.
Alternatively you can browse through podium and poster presentations by selecting the year and / or type below. You can further refine your search using tags or use the search bar.

Search

RSS Abstracts 476 Expand/Collapse
- RSS 2013 64 Expand/Collapse
  - RSS Poster 24 Expand/Collapse
  - RSS Podium 40 Expand/Collapse
- RSS 2014 36 Expand/Collapse
  - RSS Podium 36 Expand/Collapse
- RSS 2015 49 Expand/Collapse
  - RSS Poster 20 Expand/Collapse
  - RSS Podium 29 Expand/Collapse
- RSS 2016 45 Expand/Collapse
  - RSS Poster 18 Expand/Collapse
  - RSS Podium 27 Expand/Collapse
- RSS 2017 40 Expand/Collapse
  - RSS Poster 15 Expand/Collapse
  - RSS Podium 25 Expand/Collapse
- RSS 2018 47 Expand/Collapse
  - RSS Poster 22 Expand/Collapse
  - RSS Podium 25 Expand/Collapse
- RSS 2019 48 Expand/Collapse
  - RSS Poster 25 Expand/Collapse
  - RSS Podium 23 Expand/Collapse
- RSS 2021 15 Expand/Collapse
  - RSS Poster 10 Expand/Collapse
  - RSS Podium 6 Expand/Collapse
- RSS 2022 46 Expand/Collapse
  - RSS Poster 23 Expand/Collapse
  - RSS Podium 23 Expand/Collapse
- RSS 2023 46 Expand/Collapse
  - RSS Poster 23 Expand/Collapse
  - RSS Podium 23 Expand/Collapse
- RSS 2024 40 Expand/Collapse
  - RSS Poster 18 Expand/Collapse
  - RSS Podium 22 Expand/Collapse

Categories: Abstracts, 2013, Poster

The use of extracorporeal shockwave therapy (ESWT) for severe resistant plantar fasciitis

E. Choong, R. Brown, S. Clint

¹Cheltenham General Hospital, Physiotherapy Department, Cheltenham, United Kingdom

²Cheltenham General Hospital, Orthopaedic Department, Cheltenham, United Kingdom

Introduction: Plantar fasciitis (PF) is typically self-limiting and the vast majority of patients are successfully treated with conservative measures. However, for a small number of patients, symptoms persist and may require alternative treatment. In 2009, NICE found ESWT to be a safe treatment option for refractory PF and recommended further clinical research. This audit aimed to investigate the effectiveness of ESWT for resistant PF.

Methods: Patient enrolment took place during an 18-month period in an outpatient department of a DGH. Patients were recruited from referring primary care providers (GPs, podiatrists, physiotherapists). Inclusion criteria included a history of at least 3 months of chronic plantar heel pain that proved resistant to at least 3 months of conservative treatment. Patients with bilateral symptoms were not excluded. Diagnosis was confirmed by clinical examination and by excluding other causes of pain with an MRI scan. A total of 32 heels (25 patients) received 3 shockwave interventions, each two weeks apart. 2000 pulses were delivered each intervention using the Swiss Dolorclast radial shockwave device without local anaesthetic. Effectiveness was measured using the Foot Function Index (FFI) pre-treatment and 3 months post-treatment. A reduction in FFI >10% was defined as a responder.

Results: There were 7 missing outcomes at 3 months, giving a total of 25 completed outcome scores. At baseline, the mean FFI score was 53.0% +/-21.0. At 3 months, the mean FFI score was 28.7% +/-26.6. The mean difference was 24.3% (95% CI: [13.88-34.84]: P< 0.0001). 14/25 heels (56%) achieved >10% reduction in FFI scores at 3 months. No side effects were observed.

Conclusion: This audit demonstrated that ESWT is a safe treatment option for the management of severe resistant PF. However, due to the small sample, it is not possible to provide robust clinical evidence of its effectiveness. Further research is warranted.

Print

Tags: Plantar Fasciitis

Click thumbnail below to view poster / thumbnail:

Archive of Abstracts